- Strong sales generation and associated production efficiencies improve the net loss by over AED 200 million
Ras Al Khaimah – On the 18th of April 2021, the shareholders of Gulf Pharmaceutical Industries (JULPHAR), one of the largest pharmaceutical manufacturers in the Middle East and Africa, approved the Board report of the company’s activities and financial position for the financial year ending 31 December 2020 at the company’s Annual General Meeting.
Over the last financial year, Julphar recorded net sales of AED 581.2 million, a 93% increase against 2019 net sales of AED 301.5 million. Additionally, the company revealed that losses amounted to AED 317.4 million that includes AED 201.3 million one-time effects, compared to a loss of AED 518.9 million in the previous year, a substantial reduction of more than AED 200 million due to much-improved sales generation and associated production efficiency improvements and successful market strategies.
Under the new leadership, Julphar has made significant and positive strides since it began its transformational journey last year. Following the successful reinspection of its facilities and obtaining the GCC approval in April 2020, Julphar restarted exports to key markets in the GCC, such as Saudi Arabia, Oman, and Kuwait. As a result, the company has made considerable progress towards reaching profitability and generated an AED 7.1 million positive EBITDA before one-time effects.
Sh. Saqer Humaid Al Qasimi, Chairman of the Board, Julphar, said: “We thank and express our gratitude to all shareholders, government agencies, and business partners for their resolute trust and unwavering support over the past year. I am also grateful for the exceptional dedication, commitment, and enthusiasm of our people who have played a vital role in the success of Julphar. We have been conducting a comprehensive review of all areas of our business to identify cost savings and generate efficiency improvements. As a result, we expect further gross margin improvements in 2021 and project a return to profitability in the second half of the year.”
Dr. Essam Farouk, Chief Executive Officer of Julphar, said: “As we move forward, we will consolidate our market position and expand our market share in the MENA region. The ongoing transformation program will make the company more competitive in our core markets.”
“Last year, the capital restructuring marked a major milestone in our transformation. As we continue our journey in 2021, we are confident that the company is well on track to regain its leading market position in the MENA region, and of course, continue in our mission to ensure that people in our region and across the world have greater access to high quality and affordable healthcare solutions.” Dr. Essam added.
In the fight against COVID-19, Julphar has also been working closely with the UAE government and has entered a manufacturing agreement to produce the Hayat-Vax vaccine to meet local and regional demand. Julphar has dedicated a large part of its injectable vials filling capacity for vaccine production.
During last year’s assembly, Julphar’s Board of Directors approved a special resolution for a capital reduction followed by a capital increase by way of rights issue. With the aim to strengthen the company’s capital position and improve its debt profile, the AED 500 million rights issue was successfully completed and more than two times oversubscribed.
Several new appointments were made in Julphar’s senior management team in 2020 who are entrusted with driving the company’s expansion strategy forward. In the coming years, Julphar will invest in their workforce by launching new training and development programs that address the evolving market demands and requirements.
Julphar will continue to focus on building new alliances and partnerships to strengthen the company’s revenues and expand its distribution footprint. The company aims to augment its 150+ product portfolio by launching new and innovative products to its existing and newly introduced high value therapy areas.
-Ends-
About Julphar
Julphar is one of the largest pharmaceutical manufacturers in the Middle East and Africa, and for almost four decades, the company has been delivering high quality, innovative and affordable healthcare solutions to families across the globe. Established under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi in 1980, Julphar employs more than 3,000 people and distributes pharmaceutical products to more than 50 countries on five continents.
Julphar’s business is centered on three core business units – Julphar Diabetes Solutions, General Medicines and its consumer division, Julphar Life – which target major therapeutic segments including Gastrology, Pain Management, Wound Care, Antibiotics and Cardio-metabolism. Julphar has 16 internationally accredited facilities in Africa, Middle East and Asia. In 2012, Julphar became one of the largest producers of Insulin with its UAE-based biotechnology production unit.
For more information, visit http://www.julphar.net
Media contact: Corporate Communication, Julphar.
Mail: adel.khaled@julphar.net
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
